5-amino-1mq nnmt inhibitor study obesity — 50mg | (NAD+ Axis) 5-Amino-1MQ 50mg (60 Capsules)

Best published PK (Awosemo et al., 2021, rats): ~38% oral bioavailability, ~6 to 7 hr oral half-life

The authors framed the data as first clear evidence that NNMT inhibitors constitute a viable pharmacological approach to enhance regenerative capacity in aged skeletal muscle

No FDA status Not FDA-approved as a drug These compounds are not interchangeable

Anyone pregnant, breastfeeding, or with a diagnosed metabolic, hepatic, or endocrine condition falls entirely outside any studied context and should not be a subject of self-directed use

5-amino-1mq is commonly available in oral capsule form and appears to have reasonable oral bioavailability based on rat pharmacokinetic studies

Products sold as 5-Amino-1MQ capsules or vials are marketed under research-use-only labeling